A Phase 2 interventional study of GSK1349572 (Cohort I) and GSK1349572 (Cohort II) in Infection, Human Immunodeficiency Virus, sponsored by ViiV Healthcare. Completed at 26 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-12-04.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Integrase is an enzyme produced by HIV so that the virus can multiply in the human body. GSK1349572 is a new drug in the integrase inhibitor class that prevents the enzyme from working properly and therefore prevents the virus from multiplying.
GSK1349572 has shown to be effective against viruses in a short-term monotherapy study in adults with no previous exposure to integrase inhibitors. The purpose of this study is to determine whether GSK1349572 is effective in the treatment of HIV-infected patients who no longer respond to treatment with the approved integrase inhibitor raltegravir and carry viruses with resistance to this drug. The safety and efficacy of GSK1349572 50mg once daily in combination with the background HIV drugs previously administered (unless discontinuation of a particular drug is required) will be assessed over 10 days (functional monotherapy phase), followed by the evaluation of the safety and efficacy of GSK1349572 given with a new optimised background regimen from Day 11 through at least Week 24.
Study (ING112961) is a Phase IIb, multicentre, open-label, single arm, two cohorts, pilot study to assess the antiviral activity of GSK1349572 containing regimen in HIV-1 infected ART-experienced adults with raltegravir (RAL) resistance. The study will include approximately 50 ART-experienced subjects with either current or past virologic failure to RAL. All subjects must harbour isolates with RAL resistance mutations at Screening. Subjects should also have documented genotypic and/or phenotypic resistance to at least one compound from each of three or more of the approved classes of ART (including integrase inhibitors [INIs]). Subjects with current RAL virologic failure will substitute RAL with GSK1349572 50mg once daily and continue the remaining components of their failing regimen through Day 10. Subjects with historical RAL virologic failure will add GSK1349572 50mg once daily to their failing regimen through Day 10. On Day 11 all subjects will continue GSK1349572 and optimize their background therapy. Antiviral activity, safety and tolerability of GSK1349572 will be evaluated at Day 11 and over time through at least Week 24.
ViiV Healthcare is the new sponsor of this study, and GlaxoSmithKline is in the process of updating systems to reflect the change in sponsorship.
2,096 studies on the registry are indexed under Infections; 364 are open to participants now.
This study's enrollment of 51 is below the median of 113 across 1,304 interventional studies indexed under Infections.
Browse Infections studies →ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single Arm, Cohort I
Drug: GSK1349572 (Cohort I)
Single Arm, Cohort II
Drug: GSK1349572 (Cohort II)
50 mg once daily
Also known as: Dolutegravir
50 mg twice daily
Also known as: Dolutegravir
Number of Participants Who Achieved HIV-1 RNA <400 Copies (c)/Milliliter (mL) or at Least 0.7 log10 c/mL Below Their Baseline Value at Day 11
The number of participants who acheived Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) \<400 c/mL or at least 0.7 log10 c/mL below their Baseline value at Day 11 was assessed. The last observation was carried forward if a participant had missed the Day 11 visit. The Baseline observation was carried forward if a participant had discontinued the treatment before Day 11. Blood samples for assessment of HIV-1 RNA levels were collected at Baseline and Day 11.
Time frame: Baseline (Day 1) and Day 11
Mean Change From Baseline in Plasma HIV-1 RNA at Day 6 to 8, Day 11, Weeks 4, 12, 24, 48, 72, 96, From Week 108 Every 12 Weeks up to Study Completion
Mean change from Baseline in Plasma HIV-1 RNA was assessed on Day 6 to 8, Day 11, and Weeks 4, 12, 24, 48, 72, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, and 264 using data of the observed cases. Study Day 1 was considered as Baseline. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline; Day 6 to 8; Day 11; Weeks 4, 12, 24, 48, 72, 96, from 108 every 12 weeks up to study completion
Number of Participants Who Achieved Plasma HIV-1 RNA <400 c/mL and <50 c/mL at Baseline and Weeks 4, 12, 24, 48, 72, and 96: TLOVR Analysis.
The number of participants with plasma HIV-1 RNA \<400 c/mL or \<50 c/mL was assessed at Weeks 4, 12, 24, 48, 72, and 96 per the Food and Drug Administration's Time to Loss of Virological Response (TLOVR) algorithm. Using the TLOVR algorithm, participants are considered to have failed on therapy if they never achieved confirmed RNA levels below the threshold, if they had confirmed rebound of RNA above the threshold, if they made a non-permitted change in background regimen, or if they permanently discontinued investigational product for any reason.
Time frame: Baseline; Weeks 4, 12, 24, 48, 72, and 96
Proportion of Participants Who Achieved Plasma HIV-1 RNA <400 c/mL and <50 c/mL From Week 48 Every 12 Weeks up to Study Completion
The number of participants with plasma HIV-1 RNA \<400 c/mL or \<50 c/mL was assessed at Weeks 48, 72, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, and 264 using data of observed cases. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
Time frame: From Week 48 every 12 weeks up to study completion
Change From Baseline in CD4+ Cell Count at Day 11 and Weeks 4, 12, 24, 48, 72, 96, Week 108 Every 12 Weeks up to Study Completion
Change from Baseline in CD4+ cell count was assessed at Day 11 and at Weeks 4, 12, 24, 48, 72, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, and 264 . Study Day 1 was considered as Baseline. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline; Day 11; Weeks 4, 12, 24, 48, 72, 96, from Week 108 every 12 weeks up to study completion
Cmax, Cmin, and Ctau of DTG
The maximum plasma concentration (Cmax), minimum plasma concentration (Cmin), and concentration at the end of a dosing interval (Ctau) of DTG were assessed at Day 10. Blood samples for pharmacokinetic (PK) assessments were collected at pre-dose (within 15 minutes prior to dose) and 2, 3, 4, 8, and 24 hours post-dose on Day 10 for DTG 50 mg OD and pre-dose (within 15 minutes prior to dose) and 2, 3, 4 and 8 hours post morning dose and 12 hours post evening dose for DTG 50 mg BID.
Time frame: Day 10
C0 Assessment of DTG
The plasma DTG concentration immediately prior to dosing at steady state (C0) was assessed at Day 10, and Weeks 4 and 24. Blood samples for pharmacokinetic assessments were collected at pre-dose (within 15 minutes prior to dose).
Time frame: Day 10; Weeks 4 and 24
Tmax of DTG
The tmax is defined as the time of occurrence of the maximum plasma concentration (Cmax). The tmax was assessed at Day 10. Blood samples for pharmacokinetic assessments were collected at pre-dose (within 15 minutes prior to dose) and 2, 3, 4, 8, and 24 hours post-dose on Day 10 for DTG 50 mg OD and pre-dose (within 15 minutes prior to dose) and 2, 3, 4 and 8 hours post morning dose and 12 hours post evening dose for DTG 50 mg BID.
Time frame: Day 10
AUC0-24 Assessment of DTG
AUC is defined as the area under the DTG concentration-time curve as a measure of drug exposure. AUC(0-24) is defined as the area under the concentration-time curve from time zero (pre-dose) to 24 hours. AUC0-24 of DTG was assessed at Day 10. Blood samples for pharmacokinetic assessments were collected at pre-dose (within 15 minutes prior to dose) and 2, 3, 4, 8, and 24 hours post-dose on Day 10 for DTG 50 mg OD and pre-dose (within 15 minutes prior to dose) and 2, 3, 4 and 8 hours post morning dose and 12 hours post evening dose for DTG 50 mg BID.
Time frame: Day 10
Number of Participants With the Indicated HIV-1 Associated Conditions, Excluding Recurrences
The number of participants with post-Baseline emergent HIV-1 disease progression (Acquired immunodeficiency syndrome (AIDS) or death) was assessed per the Centers for Disease Control and Prevention (CDC) 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. The CDC classifies HIV infection as Category A (participants with asymptomatic HIV infection, acute HIV infection with accompanying illness, or persistent generalized lymphadenopathy), Category B (participants with symptomatic non-AIDS condition, i.e., conditions that are attributed to HIV infection or are indicative of a defect in cell-mediated immunity; or conditions are considered by physicians to have a clinical course or to require management that is complicated by HIV infection), and Category C (includes AIDS indicator conditions as defined by diagnostic or presumptive measures).
Time frame: From the day of the first dose of study drug until study completion (median 605 days for Cohort I, median 1181 days for Cohort II)
Number of Participants With HIV-1 Associated Disease Progression With the Indicated Shifts to CDC Class C or Death
The number of participants with HIV-1 disease progression (AIDS or death) was assessed per the CDC 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. The CDC classifies HIV infection as Category A (participants with asymptomatic HIV infection, acute HIV infection with accompanying illness, or persistent generalized lymphadenopathy), Category B (participants with symptomatic non-AIDS condition, i.e., conditions that are attributed to HIV infection or are indicative of a defect in cell-mediated immunity; or conditions are considered by physicians to have a clinical course or to require management that is complicated by HIV infection), and Category C (includes AIDS indicator conditions as defined by diagnostic or presumptive measures).
Time frame: From the day of the first dose of study drug until study completion (median 605 days for Cohort I, median 1181 days for Cohort II)
Number of Participants (Cumulative) With Protocol-defined Virological Failure (PDVF) at Day 11 and Weeks 8, 12, 16, 20, 24, 32, 40, 48, 60, 72, 84, 96, Week 108 Every 12 Weeks up to Study Completion
PDVF is defined in relation to Baseline plasma HIV-1 RNA levels: at Day 11, a decrease of \<0.7 log10 c/mL unless \<400 c/mL; at Weeks 8 to \<16, a decrease of \<1.0 log10 c/mL unless \<400 c/mL or an increase of \>= 1.0 log10 c/mL from nadir; and at or after Week 16, ≥400 c/mL. PDVF at Day 11 was based on a single plasma HIV-1 RNA evaluation and did not require confirmation. Confirmation testing was required for visits at or after Week 8. For the combination treatment phase, all HIV-1 RNA samples that meet a criterion for suspected PDVF must be confirmed by a second measurement performed at least 1 week but not more than 4 weeks apart from the date of the original sample.
Time frame: Day 11; Weeks 8, 12, 16, 20, 24, 32, 40, 48, 60, 72, 84, 96, from Week 108 every 12 weeks up to study completion
Number of Participants With the Indicated Genotypic Resistance at Baseline
At Baseline, the integrase genotypic results were used to document resistance to raltegravir (RAL) and for the allocation of participants to one of two genotypic groups according to their RAL signature mutations to ensure a broad range of sensitivity to DTG. These results were not used to pre-define subgroup for analysis.
Time frame: Baseline
Median Fold Change in Sensitivity to DTG by the Baseline (Day 1) IN Mutational Group
Summary of median fold change in sensitivity to DTG by Integrase (IN) mutational group was assessed. The IN mutational group comprises of the following mutations: Q148 +2, Q148 +1, mixture (participants with virus containing more than one Y143, Q148 or N155 mutation at Day 1), Y143, N155, other (participants with virus having no mutations at codons 143, 148, or 155 at Day 1). Fold change (FC) is the fold change in 50% Inhibitory Concentration (IC50) relative to the wild-type control virus.
Time frame: Baseline (Day 1)
Number of Participants With the Indicated Treatment-emergent Integrase (IN) Mutations Detected at the Time of Protocol-defined Virologic Failure (PDVF) as a Measure of Genotypic Resistance
An analysis of changes at specific amino acids in the IN coding region associated with resistance to raltegravir, elvitegravir, or DTG was performed at Day 1 and at the time of PDVF. PDVF is defined in relation to Baseline plasma HIV-1 RNA levels: at Day 11, a decrease of \<0.7 log10 c/mL unless \<400 c/mL; at Weeks 8 to \<16, a decrease of \<1.0 log10 c/mL unless \<400 c/mL or an increase of \>= 1.0 log10 c/mL from nadir; and at or after Week 16, ≥400 c/mL. PDVF at Day 11 was based on a single plasma HIV-1 RNA evaluation and did not require confirmation. Confirmation testing was required for visits at or after Week 8. For the combination treatment phase, all HIV-1 RNA samples that meet a criterion for suspected PDVF must be confirmed by a second measurement performed at least 1 week but not more than 4 weeks apart from the date of the original sample.
Time frame: From Baseline (Day 1) until study completion (median 605 days for Cohort I, median 1181 days for Cohort II)
Number of Participants With the Indicated Fold Increase in DTG FC (Fold Change in IC50 Relative to Wild-type Virus) Between Baseline and the Time of PDVF, as a Measure of Post-Baseline Phenotypic Resistance
The FC in IC50 (50% inhibitory concentration) for DTG relative to wild-type virus was determined for virus isolated at Baseline and at the time of PDVF.The number of participants with the indicated change (ratio) in the two values at the time of PDVF is presented. PDVF is defined in relation to Baseline plasma HIV-1 RNA levels: at Day 11, a decrease of \<0.7 log 10 c/mL unless \<400 c/mL; at Weeks 8 to \<16, a decrease of \<1.0 log 10 c/mL unless \<400 c/mL or an increase of \>=1.0 log 10 c/mL from nadir; and at or after Week 16, ≥400 c/mL . PDVF at Day 11 was based on a single plasma HIV-1 RNA evaluation and did not require confirmation. Confirmation testing was required for visits at or after Week 8. For the combination treatment phase, all HIV-1 RNA samples that meet a criterion for suspected PDVF must be confirmed by a second measurement performed at least 1 week but not more than 4 weeks apart from the date of original sample.
Time frame: From Baseline (Day 1) until study completion (median 605 days for Cohort I, median 1181 days for Cohort II)
Number of Participants With the Indicated Grade 3 and Grade 4 Clinical Chemistry Toxicities
Hematology and clinical chemistry data were summarized according to Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, dated December 2004. Grade 1, Mild; Grade 2, Moderate; Grade 3, Severe; Grade 4, Potentially life-threatening. Data are presented for only those parameters for which an increase to Grade 3 or Grade 4 occurred. The Grade 3 and Grade 4 clinical chemistry toxicities included: Albumin, Alkaline Phosphatase, Amylase, Aspartate Amino Transferase, Carbon dioxide content/Bicarbonate, Creatinine, Creatinine Clearance, Hypercalcemia, Hyperglycaemia, Hyperkalemia, Hypernatremia, Hypocalcemia, Hypoglycaemia, Hypokalemia, Hyponatremia, LDL Cholesterol, Magnesium, Phosphorus inorganic, and Total Bilirubin, Alanine Amino Transferase, Calcium, Chloride, Cholesterol, Creatine Kinase, Direct Bilirubin, Glucose, High Density Lipid (HDL), Cholesterol direct, Lipase, Potassium, Sodium, Total Cholesterol, Triglycerides, Urea/Blood Urine Nitrogen.
Time frame: From start of study treatment until the end of treatment visit for each participant, up to Week 264 for Cohort I and up to Week 228 for Cohort II
Number of Participants With the Indicated Grade 3 and Grade 4 Hematological Toxicities
Hematology and clinical chemistry data were summarized according to Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, dated December 2004. Grade 1, Mild; Grade 2, Moderate; Grade 3, Severe; Grade 4, Potentially life-threatening. Data are presented for only those parameters for which an increase to Grade 3 or Grade 4 occurred. The Grade 3 and Grade 4 hematological toxicities included: Hemoglobin, Platelet Count, Total Neutrophils, and White Blood Cell count.
Time frame: From start of study treatment until the end of treatment visit for each participant, up to Week 264 for Cohort I and up to Week 228 for Cohort II
Participants recruited initially to Cohort I and subsequently to Cohort II. Recruitment to Cohort I was closed 9 months before recruitment to Cohort II was opened. Recruitment was not randomized.
| Milestone | Cohort I (DTG 50 mg OD) | Cohort II (DTG 50 mg BID) |
|---|---|---|
| Started | 27 | 24 |
| Completed | 11 | 14 |
| Not completed | 16 | 10 |
| Withdrew: Adverse event | 3 | 3 |
| Withdrew: Insufficient viral load response | 12 | 3 |
| Withdrew: Protocol violation | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 3 |
The number of participants who acheived Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) \<400 c/mL or at least 0.7 log10 c/mL below their Baseline value at Day 11 was assessed. The last observation was carried forward if a participant had missed the Day 11 visit. The Baseline observation was carried forward if a participant had discontinued the treatment before Day 11. Blood samples for assessment of HIV-1 RNA levels were collected at Baseline and Day 11.
| Participants | Cohort I (DTG 50 mg OD) | Cohort II (DTG 50 mg BID) |
|---|---|---|
| Number of Participants Who Achieved HIV-1 RNA <400 Copies (c)/Milliliter (mL) or at Least 0.7 log10 c/mL Below Their Baseline Value at Day 11 | 21 | 23 |
Mean change from Baseline in Plasma HIV-1 RNA was assessed on Day 6 to 8, Day 11, and Weeks 4, 12, 24, 48, 72, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, and 264 using data of the observed cases. Study Day 1 was considered as Baseline. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| Log10 copies/mL | Cohort I (DTG 50 mg OD) | Cohort II (DTG 50 mg BID) |
|---|---|---|
| Day 6 to 8, n=27, 24 | -1.31 ± 0.71 | -1.40 ± 0.43 |
| Day 11, n=27, 24 | -1.45 ± 0.77 | -1.76 ± 0.53 |
| Week 4, n=26, 24 | -1.82 ± 1.03 | -2.06 ± 0.78 |
| Week 12, n=22, 24 | -1.94 ± 1.14 | -2.30 ± 0.93 |
| Week 24, n=18, 22 | -1.99 ± 1.08 | -2.50 ± 0.81 |
| Week 48, n=15, 20 | -2.02 ± 1.07 | -2.63 ± 0.78 |
| Week 72, n=14, 18 | -2.10 ± 1.03 | -2.71 ± 0.82 |
| Week 96, n=13, 15 | -2.06 ± 1.13 | -2.58 ± 0.77 |
| Week 108, n= 13, 17 | -1.95 ± 1.20 | -2.69 ± 0.82 |
| Week 120, n= 11, 17 | -2.09 ± 1.15 | -2.67 ± 0.85 |
| Week 132, n= 11, 17 | -1.83 ± 1.01 | -2.66 ± 0.86 |
| Week 144, n= 12, 15 | -2.08 ± 1.29 | -2.62 ± 0.94 |
| Week 156, n= 12, 15 | -2.04 ± 1.36 | -2.65 ± 0.77 |
| Week 168, n= 11, 14 | -1.77 ± 1.26 | -2.72 ± 0.89 |
| Week 180, n= 11, 10 | -1.76 ± 1.11 | -2.56 ± 0.82 |
| Week 192, n= 9, 7 | -1.87 ± 1.16 | -2.51 ± 0.98 |
| Week 204, n= 10, 6 | -1.76 ± 1.21 | -2.35 ± 0.71 |
| Week 216, n= 9, 6 | -1.61 ± 1.08 | -2.35 ± 0.71 |
| Week 228, n= 6, 4 | -1.79 ± 1.08 | -2.33 ± 0.90 |
| Week 240, n= 7, 0 | -1.63 ± 1.13 | NA ± NA |
| Week 252, n= 4, 0 | -1.72 ± 1.07 | NA ± NA |
| Week 264, n= 1, 0 | -2.90 ± NA | NA ± NA |
The number of participants with plasma HIV-1 RNA \<400 c/mL or \<50 c/mL was assessed at Weeks 4, 12, 24, 48, 72, and 96 per the Food and Drug Administration's Time to Loss of Virological Response (TLOVR) algorithm. Using the TLOVR algorithm, participants are considered to have failed on therapy if they never achieved confirmed RNA levels below the threshold, if they had confirmed rebound of RNA above the threshold, if they made a non-permitted change in background regimen, or if they permanently discontinued investigational product for any reason.
| Participants | Cohort I (DTG 50 mg OD) | Cohort II (DTG 50 mg BID) |
|---|---|---|
| Baseline, <50 c/mL | 0 | 0 |
| Week 4, <50 c/mL | 9 | 12 |
| Week 12, <50 c/mL | 13 | 16 |
| Week 24, <50 c/mL | 11 | 19 |
| Week 48, <50 c/mL | 9 | 17 |
| Week 72, <50 c/mL | 8 | NA |
| Week 96, <50 c/mL | 7 | NA |
| Baseline, <400 c/mL | 0 | 0 |
| Week 4, <400 c/mL | 16 | 17 |
| Week 12, <400 c/mL | 16 | 20 |
| Week 24, <400 c/mL | 14 | 20 |
| Week 48, <400 c/mL | 13 | 18 |
| Week 72, <400 c/mL | 12 | NA |
| Week 96, <400 c/mL | 10 | NA |
The number of participants with plasma HIV-1 RNA \<400 c/mL or \<50 c/mL was assessed at Weeks 48, 72, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, and 264 using data of observed cases. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
| Percentage of Participants | Cohort I (DTG 50 mg OD) | Cohort II (DTG 50 mg BID) |
|---|---|---|
| Week 48, <50 c/mL, n=15, 20 | 60 | 80 |
| Week 60, <50 c/mL, n=13, 18 | 69 | 94 |
| Week 72, <50 c/mL, n=14, 18 | 64 | 78 |
| Week 84, <50 c/mL, n=14, 18 | 57 | 78 |
| Week 96, <50 c/mL, n=13, 15 | 54 | 87 |
| Week 108, <50 c/mL, n=13, 17 | 54 | 88 |
| Week 120, <50 c/mL, n=11, 17 | 55 | 88 |
| Week 132, <50 c/mL, n=11, 17 | 55 | 82 |
| Week 144, <50 c/mL, n=12, 15 | 58 | 87 |
| Week 156, <50 c/mL, n=12, 15 | 67 | 93 |
| Week 168, <50 c/mL, n=11, 14 | 64 | 86 |
| Week 180, <50 c/mL, n=11, 10 | 64 | 100 |
| Week 192, <50 c/mL, n= 9, 7 | 67 | 100 |
| Week 204, <50 c/mL, n= 10, 6 | 50 | 100 |
| Week 216, <50 c/mL, n= 9, 6 | 56 | 100 |
| Week 228, <50 c/mL, n=6, 4 | 67 | 100 |
| Week 240, <50 c/mL, n=7,0 | 57 | NA |
| Week 252, <50 c/mL, n=4, 0 | 50 | NA |
| Week 264, <50 c/mL, n=1, 0 | 100 | NA |
| Week 48, <400 c/mL, n=15, 20 | 73 | 95 |
| Week 60,<400 c/mL, n=13, 18 | 92 | 100 |
| Week 72,<400 c/mL, n=14, 18 | 79 | 100 |
| Week 84,<400 c/mL, n=14, 18 | 71 | 94 |
| Week 96,<400 c/mL, n=13, 15 | 85 | 100 |
| Week 108,<400 c/mL, n=13,17 | 85 | 100 |
| Week 120,<400 c/mL, n=11, 17 | 82 | 94 |
| Week 132,<400 c/mL, n=11,17 | 82 | 94 |
| Week 144,<400 c/mL, n=12, 15 | 83 | 93 |
| Week 156,<400 c/mL, n=12, 15 | 75 | 100 |
| Week 168,<400 c/mL, n=11, 14 | 82 | 100 |
| Week 180,<400 c/mL, n=11, 10 | 73 | 100 |
| Week 192,<400 c/mL, n=9, 7 | 78 | 100 |
| Week 204,<400 c/mL, n=10, 6 | 70 | 100 |
| Week 216,<400 c/mL, n=9, 6 | 56 | 100 |
| Week 228,<400 c/mL, n=6, 4 | 67 | 100 |
| Week 240,<400 c/mL, n=7, 0 | 71 | NA |
| Week 252,<400 c/mL, n=4, 0 | 50 | NA |
| Week 264,<400 c/mL, n=1, 0 | 100 | NA |
Change from Baseline in CD4+ cell count was assessed at Day 11 and at Weeks 4, 12, 24, 48, 72, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, and 264 . Study Day 1 was considered as Baseline. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| cells per cubic millimeter (mm^3) | Cohort I (DTG 50 mg OD) | Cohort II (DTG 50 mg BID) |
|---|---|---|
| Baseline, n=27, 24 | 114 (44 to 227) | 202 (19 to 384) |
| Day 11, n=27, 24 | 34 (2 to 71) | 14 (0 to 69) |
| Week 4, n=27, 24 | 57 (33 to 108) | 35 (8 to 69) |
| Week 12, n= 22, 24 | 84 (26 to 124) | 57 (8 to 103) |
| Week 24, n=17, 22 | 78 (54 to 175) | 79 (17 to 147) |
| Week 48, n=15, 20 | 102 (29 to 160) | 106 (45 to 245) |
| Week 72, n=14, 18 | 163 (58 to 204) | 191.5 (80 to 277) |
| Week 96, n=13, 15 | 142 (75 to 202) | 189 (75 to 280) |
| Week 108, n=13, 17 | 124 (68 to 249) | 155 (91 to 276) |
| Week 120, n=11, 17 | 221 (62 to 306) | 221 (135 to 314) |
| Week 132, n=11, 17 | 97 (26 to 303) | 158 (129 to 384) |
| Week 144, n=12, 15 | 121 (28 to 284) | 278 (113 to 340) |
| Week 156, n=12, 15 | 212 (64 to 378) | 223 (131 to 309) |
| Week 168, n=11, 13 | 97 (-102 to 365) | 271 (93 to 357) |
| Week 180, n=11, 10 | 125 (55 to 327) | 224 (163 to 288) |
| Week 192, n=10, 7 | 94 (61 to 291) | 343 (304 to 429) |
| Week 204, n=10, 6 | 92 (47 to 364) | 264 (186 to 370) |
| Week 216, n=9, 6 | 172 (48 to 416) | 252 (147 to 421) |
| Week 228, n=7, 3 | 148 (66 to 357) | 417 (-12 to 633) |
| Week 240, n=7, 0 | 158 (119 to 470) | NA (NA to NA) |
| Week 252, n=4, 0 | 157 (109 to 282) | NA (NA to NA) |
| Week 264, n=1, 0 | 560 (560 to 560) | NA (NA to NA) |
The maximum plasma concentration (Cmax), minimum plasma concentration (Cmin), and concentration at the end of a dosing interval (Ctau) of DTG were assessed at Day 10. Blood samples for pharmacokinetic (PK) assessments were collected at pre-dose (within 15 minutes prior to dose) and 2, 3, 4, 8, and 24 hours post-dose on Day 10 for DTG 50 mg OD and pre-dose (within 15 minutes prior to dose) and 2, 3, 4 and 8 hours post morning dose and 12 hours post evening dose for DTG 50 mg BID.
| Micrograms per milliliter (µg/mL) | Cohort I (DTG 50 mg OD) | Cohort II (DTG 50 mg BID) |
|---|---|---|
| Cmax | 3.04 ± 38 | 5.41 ± 40 |
| Ctau | 0.69 ± 91 | 2.72 ± 70 |
| Cmin | 0.48 ± 136 | 2.61 ± 67 |
The plasma DTG concentration immediately prior to dosing at steady state (C0) was assessed at Day 10, and Weeks 4 and 24. Blood samples for pharmacokinetic assessments were collected at pre-dose (within 15 minutes prior to dose).
| µg/mL | Cohort I (DTG 50 mg OD) | Cohort II (DTG 50 mg BID) |
|---|---|---|
| C0, Day 10 | 0.51 ± 139 | 3.20 ± 69 |
| C0, Week 4 | 0.57 ± 100 | 2.55 ± 63 |
| C0, Week 24 | 0.38 ± 114 | 2.38 ± 69 |
The tmax is defined as the time of occurrence of the maximum plasma concentration (Cmax). The tmax was assessed at Day 10. Blood samples for pharmacokinetic assessments were collected at pre-dose (within 15 minutes prior to dose) and 2, 3, 4, 8, and 24 hours post-dose on Day 10 for DTG 50 mg OD and pre-dose (within 15 minutes prior to dose) and 2, 3, 4 and 8 hours post morning dose and 12 hours post evening dose for DTG 50 mg BID.
| Hours | Cohort I (DTG 50 mg OD) | Cohort II (DTG 50 mg BID) |
|---|---|---|
| Tmax of DTG | 2.97 (1.97 to 7.92) | 2.00 (0.00 to 7.87) |
AUC is defined as the area under the DTG concentration-time curve as a measure of drug exposure. AUC(0-24) is defined as the area under the concentration-time curve from time zero (pre-dose) to 24 hours. AUC0-24 of DTG was assessed at Day 10. Blood samples for pharmacokinetic assessments were collected at pre-dose (within 15 minutes prior to dose) and 2, 3, 4, 8, and 24 hours post-dose on Day 10 for DTG 50 mg OD and pre-dose (within 15 minutes prior to dose) and 2, 3, 4 and 8 hours post morning dose and 12 hours post evening dose for DTG 50 mg BID.
| Micrograms*hour per milliliter (µg*hr/mL | Cohort I (DTG 50 mg OD) | Cohort II (DTG 50 mg BID) |
|---|---|---|
| AUC0-24 Assessment of DTG | 36.46 ± 53 | 93.36 ± 50 |
The number of participants with post-Baseline emergent HIV-1 disease progression (Acquired immunodeficiency syndrome (AIDS) or death) was assessed per the Centers for Disease Control and Prevention (CDC) 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. The CDC classifies HIV infection as Category A (participants with asymptomatic HIV infection, acute HIV infection with accompanying illness, or persistent generalized lymphadenopathy), Category B (participants with symptomatic non-AIDS condition, i.e., conditions that are attributed to HIV infection or are indicative of a defect in cell-mediated immunity; or conditions are considered by physicians to have a clinical course or to require management that is complicated by HIV infection), and Category C (includes AIDS indicator conditions as defined by diagnostic or presumptive measures).
| Participants | Cohort I (DTG 50 mg OD) | Cohort II (DTG 50 mg BID) |
|---|---|---|
| Category B, Candidiasis, oropharyngeal | 3 | 2 |
| Category B, Hairy leukoplakia, oral | 2 | 0 |
| Category B, Herpes Zoster | 2 | 0 |
| Category C, Herpes simplex | 1 | 0 |
| Category C, Candidiasis, esophageal | 0 | 1 |
| Category C, Cytomegalovirus retinitis | 0 | 1 |
| Category C, Kaposi's sarcoma | 1 | 0 |
| Category C, Lymphoma, Burkitt's | 0 | 1 |
| Category C, Lymphoma, immunoblastic | 1 | 0 |
| Death, Brain mass | 1 | 0 |
| Death, Completed suicide | 0 | 1 |
| Death, Febrile bone marrow aplasia | 1 | 0 |
| Death, Immunoblastic lymphoma | 1 | 0 |
| Death, Acute pulmonary oedema | 1 | 0 |
| Death, Anaemia | 0 | 1 |
| Death, Haemochromatosis | 0 | 1 |
| Death, Hepatic fibrosis | 0 | 1 |
| Other: Cryptosporidiosis, acute intestinal | 0 | 1 |
| Other: leukoplasia of both side of the tongue | 1 | 0 |
The number of participants with HIV-1 disease progression (AIDS or death) was assessed per the CDC 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. The CDC classifies HIV infection as Category A (participants with asymptomatic HIV infection, acute HIV infection with accompanying illness, or persistent generalized lymphadenopathy), Category B (participants with symptomatic non-AIDS condition, i.e., conditions that are attributed to HIV infection or are indicative of a defect in cell-mediated immunity; or conditions are considered by physicians to have a clinical course or to require management that is complicated by HIV infection), and Category C (includes AIDS indicator conditions as defined by diagnostic or presumptive measures).
| Participants | Cohort I (DTG 50 mg OD) | Cohort II (DTG 50 mg BID) |
|---|---|---|
| From CDC class A to CDC class C | 0 | 2 |
| From CDC class B to CDC class C | 0 | 2 |
| From CDC class C to new CDC class C | 1 | 0 |
| From CDC Class A, B, or C to death | 3 | 2 |
PDVF is defined in relation to Baseline plasma HIV-1 RNA levels: at Day 11, a decrease of \<0.7 log10 c/mL unless \<400 c/mL; at Weeks 8 to \<16, a decrease of \<1.0 log10 c/mL unless \<400 c/mL or an increase of \>= 1.0 log10 c/mL from nadir; and at or after Week 16, ≥400 c/mL. PDVF at Day 11 was based on a single plasma HIV-1 RNA evaluation and did not require confirmation. Confirmation testing was required for visits at or after Week 8. For the combination treatment phase, all HIV-1 RNA samples that meet a criterion for suspected PDVF must be confirmed by a second measurement performed at least 1 week but not more than 4 weeks apart from the date of the original sample.
| Participants | Cohort I (DTG 50 mg OD) | Cohort II (DTG 50 mg BID) |
|---|---|---|
| Day 11 | 6 | 1 |
| Week 8 | 7 | 3 |
| Week 12 | 9 | 3 |
| Week 16 | 10 | 5 |
| Week 20 | 10 | 5 |
| Week 24 | 12 | 5 |
| Week 32 | 12 | 5 |
| Week 40 | 12 | 5 |
| Week 48 | 13 | 5 |
| Week 60 | 13 | 5 |
| Week 72 | 14 | 6 |
| Week 84 | 15 | 6 |
| Week 96 | 16 | 6 |
| Week 108 | 16 | 6 |
| Week 120 | 16 | 6 |
| Week 132 | 16 | 6 |
| Week 144 | 16 | 7 |
| Week 156 | 16 | 7 |
| Week 168 | 16 | 7 |
| Week 180 | 16 | 7 |
| Week 192 | 16 | 7 |
| Week 204 | 16 | 7 |
| Week 216 | 17 | 7 |
| Week 228 | 18 | 7 |
| Week 240 | 18 | NA |
| Week 252 | 18 | NA |
| Week 264 | 18 | NA |
At Baseline, the integrase genotypic results were used to document resistance to raltegravir (RAL) and for the allocation of participants to one of two genotypic groups according to their RAL signature mutations to ensure a broad range of sensitivity to DTG. These results were not used to pre-define subgroup for analysis.
| Participants | Cohort I (DTG 50 mg OD) | Cohort II (DTG 50 mg BID) |
|---|---|---|
| Q148 + 2 | 3 | 2 |
| Q 148 + 1 | 4 | 8 |
| Mixture | 2 | 1 |
| Y143 | 12 | 6 |
| N155 | 4 | 6 |
| Other | 2 | 1 |
Summary of median fold change in sensitivity to DTG by Integrase (IN) mutational group was assessed. The IN mutational group comprises of the following mutations: Q148 +2, Q148 +1, mixture (participants with virus containing more than one Y143, Q148 or N155 mutation at Day 1), Y143, N155, other (participants with virus having no mutations at codons 143, 148, or 155 at Day 1). Fold change (FC) is the fold change in 50% Inhibitory Concentration (IC50) relative to the wild-type control virus.
| Percentage | Cohort I (DTG 50 mg OD) | Cohort II (DTG 50 mg BID) |
|---|---|---|
| Q148 + 2, n=3, 2 | 21 (14 to 35) | 4 (2.1 to 6.0) |
| Q148 + 1, n=4, 8 | 5.5 (3.3 to 25) | 5.5 (4.1 to 8.2) |
| Mixture, n=2, 1 | 7.8 (6.5 to 9.1) | 9.48 (9.48 to 9.48) |
| Y143, n=12, 6 | 1.1 (0.6 to 1.4) | 1.2 (0.92 to 1.8) |
| N155, n=4, 6 | 1.8 (1.5 to 5.1) | 2.3 (1.3 to 4.0) |
| Other, n=2, 1 | 1.2 (0.9 to 1.5) | 0.87 (0.87 to 0.87) |
An analysis of changes at specific amino acids in the IN coding region associated with resistance to raltegravir, elvitegravir, or DTG was performed at Day 1 and at the time of PDVF. PDVF is defined in relation to Baseline plasma HIV-1 RNA levels: at Day 11, a decrease of \<0.7 log10 c/mL unless \<400 c/mL; at Weeks 8 to \<16, a decrease of \<1.0 log10 c/mL unless \<400 c/mL or an increase of \>= 1.0 log10 c/mL from nadir; and at or after Week 16, ≥400 c/mL. PDVF at Day 11 was based on a single plasma HIV-1 RNA evaluation and did not require confirmation. Confirmation testing was required for visits at or after Week 8. For the combination treatment phase, all HIV-1 RNA samples that meet a criterion for suspected PDVF must be confirmed by a second measurement performed at least 1 week but not more than 4 weeks apart from the date of the original sample.
| Participants | Cohort I (DTG 50 mg OD) | Cohort II (DTG 50 mg BID) |
|---|---|---|
| Any | 11 | 5 |
| E138T | 0 | 1 |
| N155H | 3 | 4 |
| T97A | 2 | 0 |
| E92E/Q | 0 | 1 |
| G140S | 3 | 0 |
| L74I/M | 1 | 0 |
| Q148H | 2 | 0 |
| E138E/A | 1 | 0 |
| E138E/K | 1 | 2 |
| L74I/M/I | 1 | 0 |
| L74M | 1 | 0 |
| L74I | 1 | 0 |
| T97T/A | 0 | 2 |
| Q148R | 1 | 0 |
| S147G | 3 | 0 |
| E92E/V | 0 | 1 |
| L68L/I | 1 | 0 |
The FC in IC50 (50% inhibitory concentration) for DTG relative to wild-type virus was determined for virus isolated at Baseline and at the time of PDVF.The number of participants with the indicated change (ratio) in the two values at the time of PDVF is presented. PDVF is defined in relation to Baseline plasma HIV-1 RNA levels: at Day 11, a decrease of \<0.7 log 10 c/mL unless \<400 c/mL; at Weeks 8 to \<16, a decrease of \<1.0 log 10 c/mL unless \<400 c/mL or an increase of \>=1.0 log 10 c/mL from nadir; and at or after Week 16, ≥400 c/mL . PDVF at Day 11 was based on a single plasma HIV-1 RNA evaluation and did not require confirmation. Confirmation testing was required for visits at or after Week 8. For the combination treatment phase, all HIV-1 RNA samples that meet a criterion for suspected PDVF must be confirmed by a second measurement performed at least 1 week but not more than 4 weeks apart from the date of original sample.
| Participants | Cohort I (DTG 50 mg OD) | Cohort II (DTG 50 mg BID) |
|---|---|---|
| <1 fold | 3 | 0 |
| 1-<2 fold | 4 | 2 |
| 2-<4 fold | 1 | 0 |
| 4-<8 fold | 1 | 2 |
| >=8 fold | 8 | 3 |
Hematology and clinical chemistry data were summarized according to Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, dated December 2004. Grade 1, Mild; Grade 2, Moderate; Grade 3, Severe; Grade 4, Potentially life-threatening. Data are presented for only those parameters for which an increase to Grade 3 or Grade 4 occurred. The Grade 3 and Grade 4 clinical chemistry toxicities included: Albumin, Alkaline Phosphatase, Amylase, Aspartate Amino Transferase, Carbon dioxide content/Bicarbonate, Creatinine, Creatinine Clearance, Hypercalcemia, Hyperglycaemia, Hyperkalemia, Hypernatremia, Hypocalcemia, Hypoglycaemia, Hypokalemia, Hyponatremia, LDL Cholesterol, Magnesium, Phosphorus inorganic, and Total Bilirubin, Alanine Amino Transferase, Calcium, Chloride, Cholesterol, Creatine Kinase, Direct Bilirubin, Glucose, High Density Lipid (HDL), Cholesterol direct, Lipase, Potassium, Sodium, Total Cholesterol, Triglycerides, Urea/Blood Urine Nitrogen.
| Participants | Cohort I (DTG 50 mg OD) | Cohort II (DTG 50 mg BID) |
|---|---|---|
| Albumin, Grade 3 | 0 | 0 |
| Albumin, Grade 4 | 0 | 0 |
| Alkaline Phosphatase, Grade 3 | 0 | 0 |
| Alkaline Phosphatase, Grade 4 | 0 | 0 |
| Amylase, Grade 3 | 1 | 2 |
| Amylase, Grade 4 | 1 | 0 |
| Aspartate Amino Transferase, Grade 3 | 0 | 0 |
| Aspartate Amino Transferase, Grade 4 | 0 | 0 |
| Carbon dioxide content/Bicarbonate, Grade 3 | 0 | 0 |
| Carbon dioxide content/Bicarbonate, Grade 4 | 0 | 0 |
| Creatinine, Grade 3 | 0 | 0 |
| Creatinine, Grade 4 | 0 | 0 |
| Creatinine Clearance, estimated, Grade 3 | 0 | 0 |
| Creatinine Clearance, estimated, Grade 4 | 0 | 0 |
| Hypercalcemia, Grade 3 | 0 | 0 |
| Hypercalcemia, Grade 4 | 0 | 0 |
| Hyperglycaemia, Grade 3 | 0 | 0 |
| Hyperglycaemia, Grade 4 | 0 | 0 |
| Hyperkalemia, Grade 3 | 0 | 0 |
| Hyperkalemia, Grade 4 | 0 | 0 |
| Hypernatremia, Grade 3 | 1 | 0 |
| Hypernatremia, Grade 4 | 0 | 0 |
| Hypocalcemia, Grade 3 | 0 | 0 |
| Hypocalcemia, Grade 4 | 0 | 0 |
| Hypoglycaemia, Grade 3 | 1 | 0 |
| Hypoglycaemia, Grade 4 | 0 | 1 |
| Hypokalemia, Grade 3 | 0 | 0 |
| Hypokalemia, Grade 4 | 0 | 0 |
| Hyponatremia, Grade 3 | 0 | 0 |
| Hyponatremia, Grade 4 | 0 | 0 |
| LDL Cholesterol, Grade 3 | 2 | 1 |
| LDL Cholesterol, Grade 4 | 0 | 0 |
| Magnesium, Grade 3 | 0 | 0 |
| Magnesium, Grade 4 | 0 | 0 |
| Phosphorus inorganic, Grade 3 | 4 | 3 |
| Phosphorus inorganic, Grade 4 | 0 | 0 |
| Total Bilirubin, Grade 3 | 0 | 2 |
| Total Bilirubin, Grade 4 | 0 | 1 |
| Alanine Amino Transferase ,Grade 3 | 0 | 1 |
| Alanine Amino Transferase ,Grade 4 | 0 | 0 |
| Calcium,Grade 3 | 0 | 0 |
| Calcium,Grade 4 | 0 | 0 |
| Chloride,Grade 3 | 0 | 0 |
| Chloride,Grade 4 | 0 | 0 |
| Cholesterol,Grade 3 | 1 | 1 |
| Cholesterol,Grade 4 | 0 | 0 |
| Creatine Kinase,Grade 3 | 0 | 0 |
| Creatine Kinase,Grade 4 | 0 | 0 |
| Direct Bilirubin,Grade 3 | 0 | 0 |
| Direct Bilirubin,Grade 4 | 0 | 0 |
| Glucose,Grade 3 | 1 | 0 |
| Glucose,Grade 4 | 0 | 1 |
| HDL Cholesterol direct,Grade 3 | 0 | 0 |
| HDL Cholesterol direct,Grade 4 | 0 | 0 |
| Lipase,Grade 3 | 2 | 3 |
| Lipase,Grade 4 | 1 | 1 |
| Potassium,Grade 3 | 0 | 0 |
| Potassium,Grade 4 | 0 | 0 |
| Sodium,Grade 3 | 1 | 0 |
| Sodium,Grade 4 | 0 | 0 |
| Total Cholesterol/HDLratio, Grade 3 | 0 | 0 |
| Total Cholesterol/HDLratio, Grade 4 | 0 | 0 |
| Triglycerides,Grade 3 | 0 | 2 |
| Triglycerides,Grade 4 | 0 | 0 |
| Urea/BUN,Grade 3 | 0 | 0 |
| Urea/BUN,Grade 4 | 0 | 0 |
Hematology and clinical chemistry data were summarized according to Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, dated December 2004. Grade 1, Mild; Grade 2, Moderate; Grade 3, Severe; Grade 4, Potentially life-threatening. Data are presented for only those parameters for which an increase to Grade 3 or Grade 4 occurred. The Grade 3 and Grade 4 hematological toxicities included: Hemoglobin, Platelet Count, Total Neutrophils, and White Blood Cell count.
| Participants | Cohort I (DTG 50 mg OD) | Cohort II (DTG 50 mg BID) |
|---|---|---|
| Hemoglobin, Grade 3 | 0 | 1 |
| Hemoglobin, Grade 4 | 0 | 0 |
| Platelet count, Grade 3 | 0 | 0 |
| Platelet count, Grade 4 | 0 | 0 |
| Total Neutrophils, Grade 3 | 0 | 0 |
| Total Neutrophils, Grade 4 | 0 | 2 |
| White Blood Cell count, Grade 3 | 0 | 0 |
| White Blood Cell, Grade 4 | 0 | 1 |
Collected over SAEs, non-serious AEs and laboratory toxicities were collected from start of study treatment until the end of treatment visit for each participant, up to Week 264 for Cohort I and up to Week 228 for Cohort II.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort I (DTG 50 mg OD) | — | 10/27 (37%) | 25/27 (92.6%) |
| Cohort II (DTG 50 mg BID) | — | 11/24 (45.8%) | 22/24 (91.7%) |
| Event | Cohort I (DTG 50 mg OD) | Cohort II (DTG 50 mg BID) |
|---|---|---|
| Coronary artery diseaseCardiac disorders | 0/27 | 2/24 |
| Gastroenteritis viralInfections and infestations | 0/27 | 1/24 |
| PneumoniaInfections and infestations | 0/27 | 1/24 |
| Respiratory tract infectionInfections and infestations | 0/27 | 1/24 |
| Staphylococcal abscessInfections and infestations | 0/27 | 1/24 |
| AnaemiaBlood and lymphatic system disorders | 0/27 | 1/24 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/27 | 1/24 |
| Chest discomfortGeneral disorders | 0/27 | 1/24 |
| Diabetes mellitusMetabolism and nutrition disorders | 0/27 | 1/24 |
| HaemochromatosisMetabolism and nutrition disorders | 0/27 | 1/24 |
| Event | Cohort I (DTG 50 mg OD) | Cohort II (DTG 50 mg BID) |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 8/27 | 9/24 |
| BronchitisInfections and infestations | 6/27 | 7/24 |
| PyrexiaGeneral disorders | 3/27 | 7/24 |
| CoughRespiratory, thoracic and mediastinal disorders | 5/27 | 7/24 |
| AstheniaGeneral disorders | 6/27 | 3/24 |
| Upper respiratory tract infectionInfections and infestations | 2/27 | 5/24 |
| InsomniaPsychiatric disorders | 5/27 | 2/24 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 5/27 | 2/24 |
| FatigueGeneral disorders | 0/27 | 4/24 |
| LymphadenopathyBlood and lymphatic system disorders | 2/27 | 4/24 |
| Age, Customized(Years) | Cohort I (DTG 50 mg OD) | Cohort II (DTG 50 mg BID) | Total |
|---|---|---|---|
| Years | 48 (19 to 61) | 47 (33 to 68) | 47 (19 to 68) |
| Sex: Female, Male(Participants) | Cohort I (DTG 50 mg OD) | Cohort II (DTG 50 mg BID) | Total |
|---|---|---|---|
| Female | 2 | 6 | 8 |
| Male | 25 | 18 | 43 |
| Race/Ethnicity, Customized(Participants) | Cohort I (DTG 50 mg OD) | Cohort II (DTG 50 mg BID) | Total |
|---|---|---|---|
| African American/African Heritage | 3 | 5 | 8 |
| White-Arabic/North African Heritage | 1 | 1 | 2 |
| White-White/Caucasian/European Heritage | 23 | 18 | 41 |
The record gives a start of Aug 2009, a primary completion of Nov 2010 and a completion of Jan 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2013, 2 years 11 months after primary completion. A results delay was requested in Aug 2010.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dolutegravir